{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:09Z","timestamp":1792791429586,"version":"4.5.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Toxoplasmosis is a disease caused by the protozoan\n                      <jats:italic>Toxoplasma gondii<\/jats:italic>\n                      . Infection during pregnancy can lead to congenital toxoplasmosis, which is associated with severe outcomes such as fetal abnormalities, stillbirths, and miscarriage. Current treatment options for congenital toxoplasmosis have several limitations, including low efficacy in the chronic phase of the disease and concerns about potential fetal toxicity, such as bone marrow suppression and teratogenic effects. Therefore, there is an urgent need for more effective and safer therapeutic alternatives. The Medicines for Malaria Venture (MMV) offers a collection of bioactive compounds with antiparasitic potential for drug repurposing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we evaluated three MMV Pathogen Box compounds\u2014MMV675968, MMV022478, and MMV021013\u2014for their ability to control\n                      <jats:italic>T. gondii<\/jats:italic>\n                      infection in human trophoblastic cells (BeWo) and third-trimester placental villous explants. We assessed compound toxicity, effects on the parasite\u2019s lytic cycle (including adhesion and infection), alterations in parasite morphology, and the host immune response through cytokine quantification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nontoxic concentrations of all the three compounds irreversibly inhibited parasite proliferation and interfered with early stages of the lytic cycle, including adhesion and infection. Moreover, treated\n                      <jats:italic>T. gondii<\/jats:italic>\n                      tachyzoites exhibited membrane disruption, cytoplasmic degradation, and organelle disorganization. The cytokine profile indicated that compound treatment promoted an anti-inflammatory immune response, primarily by reducing IL-8 levels. Importantly, these compounds also effectively controlled\n                      <jats:italic>T. gondii<\/jats:italic>\n                      infection in human placental explants without inducing cytotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, our findings support the potential of MMV675968, MMV022478, and MMV021013 as promising drug candidates for the treatment of congenital toxoplasmosis. MMV021013 stands out as the most promising compound, combining high predicted gastrointestinal (GI) absorption and blood\u2013brain barrier (BBB) permeability, with no predicted mutagenic, tumorigenic, irritant, or reproductive effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1673462","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:32:35Z","timestamp":1764743555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel drug candidates targeting Toxoplasma gondii in maternal\u2013fetal interface models"],"prefix":"10.3389","volume":"16","author":[{"given":"Rafael Martins","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia Carine","family":"Lima dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Paulo Oliveira","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joed Pires De","family":"Lima J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme De","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Carvalho","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Vieira","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Paschoalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosiane Nascimento","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Oliveira","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Quero","family":"Reim\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellisa Freitas","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Cota","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa Am\u00e1lia Vieira","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.sjbs.2020.11.007","article-title":"Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status","volume":"28","author":"Al-Malki","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1089\/ars.2013.5814","article-title":"Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement","volume":"23","author":"Altenh\u00f6fer","year":"2015","journal-title":"Antioxidants Redox Signal."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105488","DOI":"10.1016\/j.actatropica.2020.105488","article-title":"Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice","volume":"207","author":"Azimi-Resketi","year":"2020","journal-title":"Acta Trop."},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1095\/biolreprod.114.124115","article-title":"IL10, TGF beta1, and IFN gamma modulate intracellular signaling pathways and cytokine production to control Toxoplasma gondii infection in BeWo trophoblast cells","volume":"92","author":"Barbosa","year":"2015","journal-title":"Biol. Reproduction"},{"key":"B5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review","volume":"17","author":"Ben-Harari","year":"2017","journal-title":"Drugs R D"},{"key":"B6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrmicro1800","article-title":"Kiss and spit: the dual roles of Toxoplasma rhoptries","volume":"6","author":"Boothroyd","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1021\/jm1004368","article-title":"Small-molecule inhibitors of NADPH oxidase 4","volume":"53","author":"Borb\u00e9ly","year":"2010","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0229630","DOI":"10.1371\/journal.pone.0229630","article-title":"A screening of the MMV pathogen box\u00ae reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis","volume":"15","author":"Coelho","year":"2020","journal-title":"PLoS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.3390\/microorganisms12122602","article-title":"Antiproliferative and morphological analysis triggered by drugs contained in the medicines for malaria venture COVID-box against Toxoplasma gondii tachyzoites","volume":"12","author":"Costa","year":"2024","journal-title":"Microorganisms"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3390\/microorganisms9091960","article-title":"Promising drug targets and compounds with anti-Toxoplasma gondii activity","volume":"9","author":"Da Silva","year":"2021","journal-title":"Microorganisms"},{"key":"B11","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1051\/parasite\/2013020","article-title":"Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters","volume":"20","author":"Doliwa","year":"2013","journal-title":"Parasite"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1017\/S0031182023000999","article-title":"Anti-Toxoplasma gondii screening of MMV pandemic response box and evaluation of RWJ-67657 efficacy in chronically infected mice","volume":"150","author":"Dos Santos","year":"","journal-title":"Parasitology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/tropicalmed8120510","article-title":"Medicines for malaria venture pandemic box in vitro screening identifies compounds highly active against the tachyzoite stage of Toxoplasma gondii","volume":"8","author":"Dos Santos","year":"","journal-title":"Trop. Med. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13071-021-04769-4","article-title":"Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned","volume":"14","author":"Dubey","year":"2021","journal-title":"Parasites Vectors"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00379-17","DOI":"10.1128\/aac.00379-17","article-title":"Screening the medicines for malaria venture pathogen box across multiple pathogens reclassifies starting points for open-source drug discovery","volume":"61","author":"Duffy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jogoh.2017.12.003","article-title":"An updated literature review on maternal-fetal and reproductive disorders of Toxoplasma gondii infection","volume":"47","author":"Fallahi","year":"2018","journal-title":"J. Gynecol. Obstetrics Hum. Reproduction"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis - a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1021\/acs.jmedchem.8b01754","article-title":"Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis","volume":"62","author":"Hopper","year":"2019","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"E6956","DOI":"10.1073\/pnas.1722202115","article-title":"Human impact on the diversity and virulence of the ubiquitous zoonotic parasite Toxoplasma gondii","volume":"115","author":"Keats Shwab","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/ph14121219","article-title":"Discovery of new chemical tools against Leishmania amazonensis via the MMV pathogen box","volume":"14","author":"L\u00f3pez-Arencibia","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2023.01.31.526483","DOI":"10.1101\/2023.01.31.526483","article-title":"A drug repurposing approach reveals targetable epigenetic pathways in Plasmodium vivax hypnozoites","author":"Maher","year":"2023","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1113896","DOI":"10.3389\/fcimb.2023.1113896","article-title":"Leaf hydroalcoholic extract and oleoresin from Copaifera multijuga control Toxoplasma gondii infection in human trophoblast cells and placental explants from third-trimester pregnancy","volume":"13","author":"Mart\u00ednez","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jpids\/piu077","article-title":"Congenital toxoplasmosis","volume":"3","author":"McAuley","year":"2014","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1128\/aac.01203-07","article-title":"In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone","volume":"52","author":"Meneceur","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3389\/fmicb.2018.02587","article-title":"Drug resistance in Toxoplasma gondii","volume":"9","author":"Montazeri","year":"2018","journal-title":"Front. Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/ph18091260","article-title":"BthTX-II, an Asp49 PLA2 from Bothrops jararacussu, impairs Toxoplasma gondii infection: in vitro and Ex Vivo approaches","volume":"18","author":"Oliveira","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e01802-19","DOI":"10.1128\/aac.01802-19","article-title":"Whole-cell phenotypic screening of medicines for malaria Venture Pathogen box identifies specific inhibitors of Plasmodium falciparum late-stage development and egress","volume":"64","author":"Patra","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"856686","DOI":"10.3389\/fmicb.2022.856686","article-title":"Different drugs, same end: ultrastructural hallmarks of autophagy in pathogenic protozoa","volume":"13","author":"Pedra-Rezende","year":"2022","journal-title":"Front. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0005222","DOI":"10.1371\/journal.pntd.0005222","article-title":"Congenital toxoplasmosis in France and the United States: one parasite, two diverging approaches","volume":"11","author":"Peyron","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/pathogens8010024","article-title":"Maternal and congenital toxoplasmosis: diagnosis and treatment recommendations of a French multidisciplinary working group","volume":"8","author":"Peyron","year":"2019","journal-title":"Pathogens"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1074\/jbc.M606764200","article-title":"Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii","volume":"282","author":"Que","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10096-016-2656-2","article-title":"Is Toxoplasma gondii type related to clinical outcome in human congenital infection? Systematic and critical review","volume":"35","author":"Rico-Torres","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108457","DOI":"10.1016\/j.jbc.2025.108457","article-title":"A major Toxoplasma serine protease inhibitor protects the parasite against gut-derived serine proteases and NETosis damage","volume":"301","author":"Saffarian","year":"2025","journal-title":"J. Biol. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1021\/ci800305f","article-title":"OSIRIS, an entirely in-house developed drug discovery informatics system","volume":"49","author":"Sander","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"B37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fimmu.2019.00242","article-title":"Advances and challenges in understanding cerebral toxoplasmosis","volume":"10","author":"Schl\u00fcter","year":"2019","journal-title":"Front. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/molecules25071574","article-title":"Antimalarial agents as therapeutic tools against toxoplasmosis-a short bridge between two distant illnesses","volume":"25","author":"Secrieru","year":"2020","journal-title":"Molecules"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1080\/07391102.2022.2080113","article-title":"Identification and validation of potent inhibitor of Escherichia coli DHFR from MMV pathogen box","volume":"41","author":"Sharma","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/2229-5070.190813","article-title":"Congenital toxoplasmosis: clinical features, outcomes, treatment, and prevention","volume":"6","author":"Singh","year":"2016","journal-title":"Trop. Parasitol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpara.2020.11.001","article-title":"Control of human toxoplasmosis","volume":"51","author":"Smith","year":"2021","journal-title":"Int. J. Parasitol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"12733","DOI":"10.1074\/jbc.m112.419911","article-title":"Biochemical and immunological characterization of Toxoplasma gondii macrophage migration inhibitory factor","volume":"288","author":"Sommerville","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15625","DOI":"10.1038\/s41598-019-52176-8","article-title":"Diaminoquinazoline MMV675968 from pathogen box inhibits Acinetobacter baumannii growth through targeting of dihydrofolate reductase","volume":"9","author":"Songsungthong","year":"2019","journal-title":"Sci. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e10743","DOI":"10.7717\/peerj.10743","article-title":"A novel bicyclic 2,4-diaminopyrimidine inhibitor of Streptococcus suis dihydrofolate reductase","volume":"9","author":"Songsungthong","year":"2021","journal-title":"PeerJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e01640-17","DOI":"10.1128\/aac.01640-17","article-title":"Discovery of new inhibitors of Toxoplasma gondii via the pathogen box","volume":"62","author":"Spalenka","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"15158","DOI":"10.1038\/s41598-020-72230-0","article-title":"Copaifera spp. oleoresins impair Toxoplasma gondii infection in both human trophoblastic cells and human placental explants","volume":"10","author":"Teixeira","year":"2020","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"108771","DOI":"10.1016\/j.exppara.2024.108771","article-title":"Copaifera spp. oleoresins and two isolated compounds (ent-kaurenoic and ent-polyalthic acid) inhibit Toxoplasma gondii growth in vitro","volume":"262","author":"Teixeira","year":"2024","journal-title":"Exp. Parasitol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/toxins17020095","article-title":"Insights into the role of proteolytic and adhesive domains of snake venom metalloproteinases from bothrops spp. in the control of Toxoplasma gondii infection","volume":"17","author":"Teixeira","year":"2025","journal-title":"Toxins"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e202200600","DOI":"10.1002\/cbdv.202200600","article-title":"A drug repurposing approach to identify therapeutics by screening pathogen box exploiting SARS-CoV-2 main protease","volume":"20","author":"Tyagi","year":"2023","journal-title":"Chem. Biodivers."},{"key":"B50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/cmdc.201800755","article-title":"Unpacking the pathogen box\u2014an open source tool for fighting neglected tropical disease","volume":"14","author":"Veale","year":"2019","journal-title":"ChemMedChem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1086\/428621","article-title":"Parasitic central nervous system infections in immunocompromised hosts","volume":"40","author":"Walker","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ijantimicag.2019.08.023","article-title":"Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro","volume":"54","author":"Wang","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B53","doi-asserted-by":"publisher","first-page":"905142","DOI":"10.3389\/fimmu.2022.905142","article-title":"Toxoplasma gondii CDPK3 controls the intracellular proliferation of parasites in macrophages","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijpara.2014.09.003","article-title":"Knockout of leucine aminopeptidase in Toxoplasma gondii using CRISPR\/Cas9","volume":"45","author":"Zheng","year":"2015","journal-title":"Int. J. Parasitol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijpara.2020.03.004","article-title":"TgMAP1c is involved in apicoplast biogenesis in Toxoplasma gondii","volume":"50","author":"Zheng","year":"2020","journal-title":"Int. J. Parasitol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1673462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:32:36Z","timestamp":1764743556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1673462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":55,"alternative-id":["10.3389\/fphar.2025.1673462"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1673462","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1673462"}}